GlassScriptPhysician profile
Daniel W Koontz
NPI 1912915638
$22,736.48
in general payments reported to CMS, 2019-2025
71 companies · $2,135 in 2025
The $2,135 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,473 · 2020: $3,187 · 2021: $3,314 · 2022: $3,807 · 2023: $4,004 · 2024: $2,817 · 2025: $2,135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,881 · Education: $75.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,880.57 |
| Education | $75.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,595.63 | 2019-2025 | |
| Ucb, INC. | $1,926.11 | 2019-2025 | Fintepla, Briviact, Nayzilam |
| Alexion Pharmaceuticals, INC. | $1,326.24 | 2019-2025 | Ultomiris, Soliris |
| Neurocrine Biosciences, INC. | $1,106.94 | 2019-2025 | Ingrezza, Ongentys |
| Amgen INC. | $948.97 | 2019-2025 | Uplizna, Aimovig |
| Mdd US Operations, LLC | $915.90 | 2019-2025 | Gocovri, Gocovri, Apokyn |
| Amneal Pharmaceuticals LLC | $741.00 | 2019-2024 | Rytary, Lyvispah |
| Acadia Pharmaceuticals INC | $735.13 | 2019-2025 | Nuplazid |
| Lundbeck LLC | $733.83 | 2019-2025 | Vyepti, Rexulti |
| Tanabe Pharma America, INC. | $724.85 | 2019-2024 | |
| Biogen, INC. | $699.28 | 2019-2025 | Vumerity, Tysabri |
| Lilly USA, LLC | $693.43 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Sk Life Science, INC. | $667.65 | 2020-2024 | Xcopri |
| Allergan, INC. | $577.74 | 2019-2022 | |
| Emd Serono, INC. | $545.62 | 2019-2024 | Mavenclad |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Koontz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.